EchoGo Amyloidosis vs FibriCheck
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
EchoGo Amyloidosis is an AI-powered diagnostic aid for the early detection of cardiac amyloidosis from echocardiogram video clips, primarily for use by healthcare professionals within existing clinical workflows. FibriCheck, on the other hand, is a smartphone-based tool for patients to monitor heart rhythms and detect arrhythmias, with a professional portal for oversight. While both utilize AI in cardiology and are FDA-cleared, their distinct target conditions, input data, and user interaction models position them as adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
EchoGo Amyloidosis is an AI-powered screening tool designed to aid in the early detection of cardiac amyloidosis from echocardiogram video clips. FibriCheck is a medically certified app that helps patients monitor their heart rhythm to detect and monitor various arrhythmias, including Atrial Fibrillation (AFib).
EchoGo Amyloidosis analyzes echocardiogram video clips, specifically requiring a single apical 4-chamber echo video clip. FibriCheck utilizes smartphone camera-based photoplethysmography (PPG) technology, where patients place their finger on their smartphone camera for 60 seconds to measure heart rhythm.
EchoGo Amyloidosis serves as an AI-based screening tool to assist physicians in identifying patients at risk of cardiac amyloidosis during routine cardiovascular assessments. FibriCheck functions as a remote patient monitoring solution, empowering patients to track their heart health and enabling healthcare providers to review patient data through a dedicated portal.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy with 85% sensitivity and 93% specificity for detecting cardiac amyloidosis. FibriCheck reports a high accuracy of 98.5% for AF detection, with a sensitivity of 96.3% and specificity of 99.3%.
EchoGo Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, and operates as a cloud-based SaaS model. FibriCheck provides a healthcare professional portal/dashboard for patient monitoring and supports API-based integration into EHRs and RPM platforms.